Coronavirus treatment breakthrough: French study confirms that a combination of Hydroxychloroquine (HCQ) and Azithromycin is effective in treating COVID-19 patients.
A new study published by NIH shows that Hydroxychloroquine has been found to be more effective and potent than chloroquine in vitro treatment of coronavirus.
While the media is focused on the vaccine race and leaving the discussion of THERAPEUTICS almost completely neglected, a recent well-controlled clinical study conducted by Didier Raoult M.D/Ph.D., et. al in France showed that 100% of patients that received a combination of HCQ and Azithromycin tested negative and were virologically cured within 6 days of treatment.
According to a new unearthed paper, new evidence shows CDC knew since at least 2005 that chloroquine is effective against coronaviruses.
In the meantime, the Food and Drug Administration (FDA) has approved the ‘compassionate use’ of chloroquine to treat coronavirus patients in the United States. In addition, recent guidelines from South Korea and China report that hydroxychloroquine and chloroquine are effective antiviral therapeutic treatments for novel coronavirus.
A therapeutic agent that prevents infection with novel coronavirus is highly desirable–especially for persons with high-risk exposure (e.g healthcare professionals) as well as persons with comorbidities (heart disease, diabetes, etc) and compromised immune systems. Ground-breaking in vitro studies demonstrate the potential efficacy of hydroxychloroquine as a prophylactic for novel coronavirus infection in primate cells.
Note: Hydroxychloroquine (brand name Plaquenil) is an inexpensive, globally available drug (tablet) that was approved for widespread medical use since 1955. It is commonly used today to treat malaria, systemic lupus erythematosus, and rheumatoid arthritis.
The study is part of the initiative from an independent group of scientists and physicians working on an open-data clinical trial for the prevention of COVID-19, through the use of hydroxychloroquine in combination with other therapeutic agents. The group is now calling on President Trump to allow Americans to use the drug.
Unlike a typical commercial drug trial, the objective of the group is to share trial data with the public* and health-care professionals as close to real-time as possible (with a reasonable level of data quality assurance). Given the rapidly spreading coronavirus pandemic, the group is looking for every possible means to fast-track the effort.
You can read their draft paper HERE